Patents by Inventor Danwen Huang

Danwen Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA
    Publication number: 20210332047
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Application
    Filed: November 24, 2020
    Publication date: October 28, 2021
    Inventors: Edward A. KESICKI, Kerry W. FOWLER, Danwen HUANG, Hua Chee OOI, Amy OLIVER, Kamal Deep PURI, Fuqiang RUAN, Jennifer TREIBERG
  • Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof
    Patent number: 10906907
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of preparing such compounds are also disclosed, including the preparation and use of the compound tert-butyl (S)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate of formula (110) as a precursor to synthesize an exemplary compound disclosed in this application, (S)-2-(1-((9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: February 2, 2021
    Assignee: ICOS CORPORATION
    Inventors: Edward A. Kesicki, Kerry W. Fowler, Danwen Huang, Hua Chee Ooi, Amy Oliver, Kamal Deep Puri, Fuqiang Ruan, Jennifer A. Treiberg
  • Azetidinyloxyphenylpyrrolidine compounds
    Patent number: 10781202
    Abstract: The invention provides certain azetidinyloxyphenylpyrrolidine compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat overactive bladder.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: September 22, 2020
    Assignee: Eli Lilly and Company
    Inventors: Gary G. Deng, Danwen Huang, Cynthia Darshini Jesudason, Joshua O. Odingo
  • QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA
    Publication number: 20200017503
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Application
    Filed: May 21, 2019
    Publication date: January 16, 2020
    Inventors: Edward A. KESICKI, Kerry W. FOWLER, Danwen HUANG, Hua Chee OOI, Amy OLIVER, Kamal Deep PURI, Fuqiang RUAN, Jennifer A. TREIBERG
  • AZETIDINYLOXYPHENYLPYRROLIDINE COMPOUNDS
    Publication number: 20200002318
    Abstract: The invention provides certain azetidinyloxyphenylpyrrolidine compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat overactive bladder.
    Type: Application
    Filed: September 13, 2019
    Publication date: January 2, 2020
    Inventors: Gary G. Deng, Danwen Huang, Cynthia Darshini Jesudason, Joshua O. Odingo
  • (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta
    Patent number: 10336756
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of preparing such compounds are also disclosed, including the use of (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one as a precursor to synthesize an exemplary compound disclosed in this application, (S)-2-(1-((9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: July 2, 2019
    Assignee: ICOS CORPORATION
    Inventors: Edward A. Kesicki, Kerry W. Fowler, Danwen Huang, Hua Chee Ooi, Amy Oliver, Kamal Deep Puri, Fuqiang Ruan, Jennifer Treiberg
  • AZETIDINYLOXYPHENYLPYRROLIDINE COMPOUNDS
    Publication number: 20170240532
    Abstract: The invention provides certain azetidinyloxyphenylpyrrolidine compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat overactive bladder.
    Type: Application
    Filed: September 3, 2015
    Publication date: August 24, 2017
    Applicant: Eli Lilly and Company
    Inventors: Gary G. Deng, Danwen Huang, Cynthia Darshini Jesudason, Joshua O. Odingo
  • Azetidinyloxyphenylpyrrolidine compounds
    Patent number: 9604967
    Abstract: The invention provides certain azetidinyloxyphenylpyrrolidine compounds, particularly compounds of formula I wherein R is hydrogen or methyl, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat overactive bladder.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: March 28, 2017
    Assignee: Eli Lilly and Company
    Inventors: Danwen Huang, Joshua O. Odingo
  • AZETIDINYLOXYPHENYLPYRROLIDINE COMPOUNDS
    Publication number: 20160122322
    Abstract: The invention provides certain azetidinyloxyphenylpyrrolidine compounds, particularly compounds of formula I wherein R is hydrogen or methyl, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat overactive bladder.
    Type: Application
    Filed: January 15, 2016
    Publication date: May 5, 2016
    Inventors: Danwen Huang, Joshua O. Odingo
  • QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA
    Publication number: 20160075705
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Application
    Filed: August 13, 2015
    Publication date: March 17, 2016
    Inventors: Edward A. KESICKI, Kerry W. FOWLER, Danwen HUANG, Hua Chee OOI, Amy OLIVER, Kamal Deep PURI, Fuqiang RUAN, Jennifer TREIBERG
  • 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
    Patent number: 9149477
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: October 6, 2015
    Assignee: ICOS Corporation
    Inventors: Edward A. Kesicki, Kerry W. Fowler, Danwen Huang, Hua Chee Ooi, Amy Oliver, Kamal Deep Puri, Fuqiang Ruan, Jennifer Treiberg
  • Azetidinyloxyphenylpyrrolidine compounds
    Patent number: 9034864
    Abstract: The invention provides certain azetidinyloxyphenylpyrrolidine compounds, particularly compounds of formula I wherein R is hydrogen or methyl, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat overactive bladder.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: May 19, 2015
    Assignee: Eli Lilly and Company
    Inventors: Danwen Huang, Joshua O Odingo
  • 5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta
    Patent number: 8993583
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: March 31, 2015
    Assignee: ICOS Corporation
    Inventors: Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg, Kamal Deep Puri
  • 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta
    Patent number: 8980901
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: March 17, 2015
    Assignee: Icos Corporation
    Inventors: Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg, Kamal Deep Puri
  • QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA
    Publication number: 20140378479
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Application
    Filed: May 21, 2014
    Publication date: December 25, 2014
    Applicant: ICOS CORPORATION
    Inventors: Edward A. KESICKI, Kerry W. FOWLER, Danwen HUANG, Hua Chee OOI, Amy OLIVER, Kamal Deep PURI, Fuqiang RUAN, Jennifer TREIBERG
  • AZETIDINYLOXYPHENYLPYRROLIDINE COMPOUNDS
    Publication number: 20140275002
    Abstract: The invention provides certain azetidinyloxyphenylpyrrolidine compounds, particularly compounds of formula I wherein R is hydrogen or methyl, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat overactive bladder.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 18, 2014
    Applicant: Eli Lilly and Company
    Inventors: Gary G. DENG, Danwen HUANG, Joshua O. ODINGO
  • 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
    Patent number: 8779131
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed. An exemplary compound disclosed in this application is shown below.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: July 15, 2014
    Assignee: Icos Corporation
    Inventors: Edward A. Kesicki, Kerry W. Fowler, Danwen Huang, Hua Chee Ooi, Amy Oliver, Kamal Deep Puri, Fuqiang Ruan, Jennifer Treiberg
  • QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA
    Publication number: 20140121223
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Application
    Filed: October 8, 2013
    Publication date: May 1, 2014
    Applicant: ICOS CORPORATION
    Inventors: Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg, Kamal Deep Puri
  • QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYOSITOL 3-KINASE DELTA
    Publication number: 20140121224
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Application
    Filed: October 8, 2013
    Publication date: May 1, 2014
    Applicant: ICOS CORPORATION
    Inventors: Kerry W. FOWLER, Danwen HUANG, Edward A. KESICKI, Hua Chee OOI, Amy OLIVER, Fuqiang RUAN, Jennifer TREIBERG, Kamal Deep PURI
  • Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
    Patent number: RE44638
    Abstract: The invention provides a class of substituted quinazolinone compounds and methods of treating diseases mediated by PI3K? activity. The disclosed compounds are useful in treating diseases such as bone-resorption disorders; and cancer, especially hematopoietic cancers, lymphomas, multiple myelomas and leukemia. The compounds are also useful in disrupting or inhibiting cellular processes such as leukocyte function or accumulation, neutrophils function, lymphocyte proliferation, and endogenous immune responses.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: December 10, 2013
    Assignee: ICOS Corporation
    Inventors: Kerry W. Fowler, Danwen Huang, Edward A. Kesicki, Hua Chee Ooi, Amy Oliver, Fuqiang Ruan, Jennifer Treiberg, Kamal Deep Puri